The IVA.PA stock heads into pre-market trade on 25 Mar 2026 at €5.20 with full-year 2025 results due after U.S. hours on 30 Mar 2026. Inventiva S.A. (IVA.PA) is a clinical-stage biotech listed on EURONEXT and Nasdaq. Investors will watch revenue, cash runway, and clinical updates for the NATiV3 Phase 3 program. Meyka AI flags the earnings release as the next major catalyst for the stock.
IVA.PA stock: earnings preview and calendar
Inventiva will publish 2025 results on 30 Mar 2026 after U.S. markets. Management runs a conference call on 31 Mar 2026 at 14:00 Paris time. Analysts and investors should focus on cash position, R&D spend, and any commentary on the NATiV3 Phase 3 timetables.
A clean read on operating cash flow and guidance will matter. With EPS at -3.76, expectations remain for continued investment as the company advances lanifibranor and other programs.
IVA.PA stock technicals and trading snapshot
Shares trade at €5.20 with a day range of €5.12–€5.34 and volume 173,994 versus average volume 399,610. The 50-day average is €5.33 and the 200-day average is €4.05.
Momentum indicators show neutral-to-mild bearish bias. RSI is 47.91, MACD histogram is -0.03, and ATR is 0.31. Traders should note low relative volume and Bollinger middle band at €5.31.
IVA.PA stock valuation and financials
Inventiva shows negative earnings with EPS -3.76 and a PE that is not meaningful at -1.38. Price-to-sales is 43.97 and cash per share is €1.12. The company reports a current ratio of 2.95, indicating short-term liquidity.
Revenue per share is 0.15 and free cash flow per share is -1.29. High R&D-to-revenue at 5.31x reflects clinical spending. These metrics explain elevated valuation multiples and investor sensitivity to progress updates.
Meyka AI rates IVA.PA with a score out of 100 and forecast
Meyka AI rates IVA.PA with a score out of 100: 66.68 (Grade B, Suggestion: HOLD). This grade factors in S&P 500 and sector comparisons, financial growth, key metrics, forecasts, and analyst signals. These grades are informational and not financial advice.
Meyka AI’s forecast model projects monthly €4.85, quarterly €6.17, and yearly €5.97. Versus the current €5.20, the quarterly target implies +18.65% upside and the monthly figure implies -6.73% downside. Forecasts are model-based projections and not guarantees.
IVA.PA stock risks and near-term catalysts
Near-term catalysts include the 2025 results on 30 Mar 2026, the March 31 call, and clinical program updates for lanifibranor. Partnerships with AbbVie and Boehringer Ingelheim can influence sentiment if pipeline comments appear.
Key risks: ongoing losses, heavy R&D burn, and the need for additional financing. Sector headwinds in healthcare and biotech volatility can amplify price moves around the release.
Price targets, strategy and sector context for IVA.PA stock
For active traders, set scenario targets: conservative €4.85, base €6.17, bull €9.17 over three years. A risk-aware approach treats earnings as a binary event that can widen intraday swings.
Healthcare sector average PE is 29.05, showing Inventiva trades on development potential rather than current profits. Align position size with clinical risk and liquidity constraints.
Final Thoughts
Key takeaway: IVA.PA stock sits at €5.20 before its 2025 results on 30 Mar 2026. The print and management call on 31 Mar 2026 are likely to drive near-term volatility. Financials show negative EPS -3.76, strong R&D intensity, and €1.12 cash per share, so investors must weigh clinical progress against funding needs. Meyka AI’s model projects a quarterly target of €6.17, implying +18.65% upside versus the current price. Use the monthly €4.85 projection as a downside scenario. Remember, Meyka AI grades and forecasts are model outputs and not guarantees. Monitor the results, cash commentary, and trial updates; they will set the next trading range for Inventiva on EURONEXT.
FAQs
When will Inventiva report earnings and why does it matter for IVA.PA stock?
Inventiva will publish full-year 2025 results on 30 Mar 2026. The report matters because it will update cash runway, R&D spend, and clinical progress, all key drivers for IVA.PA stock volatility and near-term investor sentiment.
What price targets does Meyka AI give for IVA.PA stock?
Meyka AI projects a monthly €4.85, quarterly €6.17, and 3-year €9.17. The quarterly target implies +18.65% upside from €5.20. Forecasts are model-based projections and not guarantees.
What are the main risks investors should watch in IVA.PA stock?
Main risks include negative EPS (-3.76), high R&D burn, potential need for financing, and binary clinical trial outcomes. Sector volatility in biotechnology can magnify price moves around earnings.
How do technical indicators read for IVA.PA stock before earnings?
Technicals are mixed. RSI is 47.91, MACD histogram -0.03, and 50-day average €5.33. Volume is below average, suggesting lower conviction ahead of the earnings event.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
What brings you to Meyka?
Pick what interests you most and we will get you started.
I'm here to read news
Find more articles like this one
I'm here to research stocks
Ask our AI about any stock
I'm here to track my Portfolio
Get daily updates and alerts (coming March 2026)